Development of Nephrotic Syndrome in a Patient with Rheumatoid Arthritis Treated with Certolizumab

J Rheumatol. 2016 Sep;43(9):1770-2. doi: 10.3899/jrheum.160147.

Authors

Ronald R Butendieck Jr¹, Tanya Bhattacharya², Xochiquetzal Geiger³

Affiliations

¹ Division of Rheumatology, Department of Medicine, Mayo Clinic; Butendieck.Ronald@mayo.edu.
² Preliminary Internal Medicine Resident, Department of Medicine, Mayo Clinic;
³ Assistant Professor of Laboratory Medicine and Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.

PMID: 27587019
DOI: 10.3899/jrheum.160147

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Arthritis, Rheumatoid / diagnosis
Arthritis, Rheumatoid / drug therapy*
Biopsy, Needle
Certolizumab Pegol / adverse effects*
Certolizumab Pegol / therapeutic use
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Follow-Up Studies
Humans
Immunohistochemistry
Middle Aged
Nephrotic Syndrome / chemically induced*
Nephrotic Syndrome / pathology*
Recovery of Function
Severity of Illness Index
Withholding Treatment

Substances

Certolizumab Pegol